Patents matching “combination”

US 10369142

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC · Granted Aug 6, 2019 · Expires Aug 1, 2039

US 10357553

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Jul 23, 2019 · Expires Jul 18, 2039

US 10286065

Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

The Board of Regents of the University of Texas System · Granted May 14, 2019 · Expires May 9, 2039

US 10272099

Tumor-selective combination therapy

The Board of Regents of the University of Texas System · Granted Apr 30, 2019 · Expires Apr 25, 2039

US 10238698

Biomarkers and combination therapies using oncolytic virus and immunomodulation

The Board of Regents of the University of Texas System · Granted Mar 26, 2019 · Expires Mar 21, 2039

US 10232041

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS PTY LTD · Granted Mar 19, 2019 · Expires Mar 14, 2039

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

US 10213389

Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

RECRO GAINESVILLE LLC · Granted Feb 26, 2019 · Expires Feb 21, 2039

US 10206932

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Feb 19, 2019 · Expires Feb 14, 2039

US 10172840

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

VTV THERAPEUTICS LLC · Granted Jan 8, 2019 · Expires Jan 3, 2039

US 10167337

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System · Granted Jan 1, 2019 · Expires Dec 27, 2038

US 10159727

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Dec 25, 2018 · Expires Dec 20, 2038

US 10143721

Combination product for the prevention of sexually transmitted infections

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Dec 4, 2018 · Expires Nov 29, 2038

US 10137104

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. · Granted Nov 27, 2018 · Expires Nov 22, 2038

US 10130618

Pharmaceutical combinations of dabigatran and proton pump inhibitors

SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI · Granted Nov 20, 2018 · Expires Nov 15, 2038

US 2018326059

COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

GANYMED PHARMACEUTICALS AG [DE] · Granted Nov 15, 2018 · Expires Nov 10, 2038

US 10086061

Combination purified inactivated vaccine for flaviviruses

The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research · Granted Oct 2, 2018 · Expires Sep 27, 2038

US 10064846

Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

VTV THERAPEUTICS LLC · Granted Sep 4, 2018 · Expires Aug 30, 2038

US 10023637

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System · Granted Jul 17, 2018 · Expires Jul 12, 2038

US 10016437

Drug combinations and uses in treating a coughing condition

Infirst Healthcare Limited · Granted Jul 10, 2018 · Expires Jul 5, 2038

US 10016476

Nutrient combinations for affecting an aging process

BioMarker Pharmaceuticals, Inc. · Granted Jul 10, 2018 · Expires Jul 5, 2038

US 10010587

IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Nektar Therapeutics · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 9980956

Methods and therapeutic combinations for treating tumors

The Board of Regents of the University of Texas System · Granted May 29, 2018 · Expires May 24, 2038

US 9968674

Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody

REGENERON PHARMACEUTICALS, INC. · Granted May 15, 2018 · Expires May 10, 2038